The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms

被引：47
|
作者：
Holmstrom, M. O. [1 ,2 ]
Hjortso, M. D. [2 ]
Ahmad, S. M. [2 ]
Met, O. [2 ,3 ]
Martinenaite, E. [2 ]
Riley, C. [1 ]
Straten, P. [2 ]
Svane, I. M. [2 ,3 ]
Hasselbalch, H. C. [1 ]
Andersen, M. H. [2 ,4 ]
机构：
[1] Zealand Univ Hosp, Dept Hematol, Roskilde, Denmark
[2] Univ Copenhagen, Dept Hematol, Ctr Canc Immune Therapy, Herlev Hosp, Herlev, Denmark
[3] Univ Copenhagen, Dept Oncol, Herlev Hosp, Herlev, Denmark
[4] Univ Copenhagen, Dept Immunol & Microbiol, Copenhagen, Denmark
来源：
LEUKEMIA | 2017年 / 31卷 / 02期
关键词：
POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; DISORDERS; JAK2;
D O I：
10.1038/leu.2016.290
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：495 / 498
页数：5
相关论文
共 50 条
  • [21] JAK2V617F allele burden in patients with myeloproliferative neoplasms
    Alshemmari, Salem H.
    Rajaan, Reshmi
    Ameen, Reem
    Al-Drees, Mohammad A.
    Almosailleakh, Marwa R.
    ANNALS OF HEMATOLOGY, 2014, 93 (05) : 791 - 796
  • [22] The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms
    Sahin, Ezgi
    Yonal-Hindilerden, Ipek
    Hindilerden, Fehmi
    Aday, Aynur
    Nalcaci, Meliha
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2022, 52 (01) : 150 - 165
  • [23] Calreticulin Mutation in JAK2V617F Negative Myeloproliferative Neoplasms - The Beaumont Experience
    Sikdar, Soma
    Prada, Anne
    Crisan, Dominita
    LABORATORY INVESTIGATION, 2015, 95 : 378A - 378A
  • [24] Identification of JAK2V617F Mutation on Myeloproliferative Disorders in Medan
    Anggraini, Dwi Rita
    Hidayat
    Sitorus, Mega Sari
    PROCEEDINGS OF THE 1ST PUBLIC HEALTH INTERNATIONAL CONFERENCE (PHICO 2016), 2016, 1
  • [25] Leukocytosis, JAK2V617F Mutation, and Hemostasis in Myeloproliferative Disorders
    Marchetti, Marina
    Falanga, Anna
    PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2007, 36 (3-4) : 148 - 159
  • [26] Thrombosis in myeloproliferative neoplasia Influence of the mutation JAK2V617F
    Guy, Alexandre
    James, Chloe
    M S-MEDECINE SCIENCES, 2019, 35 (8-9): : 651 - 658
  • [27] A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms
    Kilpivaara, Outi
    Mukherjee, Semanti
    Schram, Alison M.
    Wadleigh, Martha
    Mullally, Ann
    Ebert, Benjamin L.
    Bass, Adam
    Marubayashi, Sachie
    Heguy, Adriana
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    Offit, Kenneth
    Stone, Richard M.
    Gilliland, D. Gary
    Klein, Robert J.
    Levine, Ross L.
    NATURE GENETICS, 2009, 41 (04) : 455 - 459
  • [28] A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms
    Outi Kilpivaara
    Semanti Mukherjee
    Alison M Schram
    Martha Wadleigh
    Ann Mullally
    Benjamin L Ebert
    Adam Bass
    Sachie Marubayashi
    Adriana Heguy
    Guillermo Garcia-Manero
    Hagop Kantarjian
    Kenneth Offit
    Richard M Stone
    D Gary Gilliland
    Robert J Klein
    Ross L Levine
    Nature Genetics, 2009, 41 : 455 - 459
  • [29] JAK2V617F mutation detection in myeloproliferative disorders (MPD)
    Bakkus, M. H. C.
    Trullemans, F.
    Demanet, C.
    De Waele, M.
    ACTA CLINICA BELGICA, 2006, 61 (02): : 110 - 110
  • [30] Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms
    João Agostinho Machado-Neto
    Bruna Alves Fenerich
    Renata Scopim-Ribeiro
    Christopher A. Eide
    Juan Luiz Coelho-Silva
    Carlos Roberto Porto Dechandt
    Jaqueline Cristina Fernandes
    Ana Paula Nunes Rodrigues Alves
    Priscila Santos Scheucher
    Belinda Pinto Simões
    Luciane Carla Alberici
    Lorena Lôbo de Figueiredo Pontes
    Cristina E. Tognon
    Brian J. Druker
    Eduardo Magalhães Rego
    Fabiola Traina
    Cell Death & Disease, 9
12345